Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib Plus Nivolumab in Previously-Treated Metastatic Renal Cell Cancer
NCT02899078Phase 2Completed
- Sponsor
- University of California, Davis
- Start
- Nov 2016
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in renal cell carcinoma (RCC), sponsored by University of California, Davis. Started Nov 2016; status: completed.
02
Drugs
ibrutinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02899078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02899078.